Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Mar 2.
Published in final edited form as: Bull Math Biol. 2019 May 14;81(7):2396–2427. doi: 10.1007/s11538-019-00611-2

Spatial model for oncolytic virotherapy with lytic cycle delay

Jiantao Zhao 1,2, Jianjun Paul Tian 1,3,*
PMCID: PMC8890613  NIHMSID: NIHMS1774251  PMID: 31089864

Abstract

We formulate a mathematical model of functional partial differential equations for oncolytic virotherapy which incorporates virus diffusivity, tumor cell diffusion, and the viral lytic cycle based on a basic oncolytic virus dynamics model. We conduct a detailed analysis for the dynamics of the model and carry out numerical simulations to demonstrate our analytic results. Particularly, we establish the positive invariant domain for the ω limit set of the system, and show that the model has three spatially homogenous equilibrium solutions. We prove that the spatially uniform virus-free steady state is globally asymptotically stable for any viral lytic period delay and diffusion coefficients of tumor cells and viruses when the viral burst size is smaller than a critical value. We obtain the conditions, for example, the ratio of virus diffusion coefficient to that of tumor cells is greater than a value and the viral lytic cycle is greater than a critical value, under which the spatially uniform positive steady state is locally asymptotically stable. We also obtain conditions under which the system undergos Hopf bifurcations, and stable periodic solutions occur. We point out medical implications of our results which are difficult to obtain from models without combining diffusive properties of viruses and tumor cells with viral lytic cycles.

Keywords: Oncolytic virotherapy, functional reaction-diffusion equations, stability, Hopf bifurcation

1. Introduction

Oncolytic viruses are genetically altered viruses that can infect and multiply in cancer cells but leave healthy normal cells intact. Oncolytic viruses are of two types: oncolytic wild viruses that naturally occur preferentially in human cancer cells, and gene-modified viruses that are engineered to achieve selective oncolysis. Wild type viruses have shown a limited oncolytic efficacy in some preclinical trials, while gene-modified viruses seem to have a great potency of oncolysis [1–3]. Before 1990s, case studies and small trials of various viruses in cancer therapy were reported [4]. Since 1990s, genetic engineering began to be used for oncolytic viruses [5]. So far, many types of viruses have been modified for experiments [6], and some oncolytic viruses have been approved for human clinic trials [7]. However, the full potential of oncolytic viruses seem still not to have been reached [8]. One major challenge is how to make viruses spread thoroughly into solid tumors [9]. Understanding of the spreading dynamics of oncolytic viruses through tumors can help to overcome this difficulty, and possibly to develop strategies for clinical applications.

Mathematical modeling can allow us to explore the whole spectrum of possible outcomes, and provide rationales to optimize treatments. Several attempts have been made to understand and characterize viral dynamics by mathematical models, see for example [10, 11, 15, 17]. These mathematical models can be divided into two classes roughly. One class uses ordinary differential equations (ODEs) including delay differential equations (DDEs) [12, 13, 16, 18–28], and the other uses partial differential equations (PDEs) [11, 14, 17, 29–32]. For PDE models of oncolytic virotherapy, most of them use ideas from fluid dynamics to model solid tumor growth where tumor cells convect in the fluid velocity field within the tumor and viruses simply diffuse within the tumor. All these modeling studies have provided certain insights to viral therapy. One study by Jain and colleagues particularly emphasizes the importance of the diffusive property of viruses [9]. However, it is well known that the growth of solid tumors, particularly, brain tumor gliomas, also shows characters of cell diffusion [33]. It is, therefore, appropriate to combine diffusive tumor growth with virus diffusion into one mathematical model.

The viral lytic cycle is the time period of the intracellular viral life cycle starting from the time when a virus enters a cell to the time when a certain number (viral burst size) of newly replicated viruses come out upon the cell lysis. It is an important parameter of viral dynamics. The article [19] was the first to incorporate the viral lytic cycle as a delay parameter in mathematical model for oncolytic viral therapy.

In this study, building on a basic mathematical model for oncolytic viral dynamics [18, 19], we combine the viral lytic cycle, tumor cell diffusion, and virus diffusion into a system of functional partial differential equations as a spatial model for oncolytic viral therapy. Our spatial model considers a brain as a domain in ℝ3 where a brain tumor grows and three populations, tumor cells, infected tumor cells, and intercellular free viruses, interact with each other. We conduct a detailed analysis and computational demonstrations.

Although our analysis focuses on long-term (asymptotical) dynamical behaviors, we also obtain short-term information about virus and cell distributions which may also give insights to experiments and treatments. Comparing with non-spatial and non-delay models, our model reveals more relevant details of viral therapy. For example, when the ratio of diffusion coefficients between viruses and tumor cells is greater than a particular value, the spatially homogeneous equilibrium solution is stable for any length of the viral lytic cycle. A possible medical implication is that if we can genetically make oncolytic viruses diffuse faster than tumor cell diffuse, the time period of the viral lytic cycle will not affect the stabilization of treatments and may improve over all efficacy of treatments. This mathematical result does not contradict the fact that there is a functional relation between the viral lytic cycle and burst size which reveals that at a critical lytic cycle time, Hopf bifurcations occur in the model system [18, 19]. In fact, for our spatial model, we also obtain a similar functional relation of bifurcation diagram for different range of parameter values. In addition, the diffusion coefficients of viruses and tumor cells with viral lytic cycle length have a combined effect on dramatic changes of the solutions, for example, the occurrence of Hopf bifurcations and occurrence of stable periodic solutions. This theoretical result may explain various outcomes of oncolytic viral therapies in the current experimental research. Therefore, combining diffusive property of viruses and tumor cells with viral lytic cycle into one mathematical model is necessary to further our understanding for oncolytic viral therapy.

The rest of the paper is organized as follows. In section 2, we review some basic mathematical models for oncolytic viral therapy, and introduce our model in terms of delay reaction-diffusion equations. In section 3, we mathematically analyze the dynamics of our functional PDE model for a solid tumor in ℝ3. In section 4, we demonstrate some numerical simulations in a two dimensional spatial domain to support the theoretical results. In section 5, we highlight our results which cannot be obtained without virus and cell diffusion, explain some medical implications of our results, and discuss and compare several revelent results in the literature. In Appendix, we carry out analysis for properties of periodic solutions arising from Hopf bifurcations of functional partial differential equations which provides some guidance for numerical simulations, and also briefly describe numerical methods we use to solve our model.

2. Mathematical Model

In the paper [18], a basic mathematical model for oncolytic virotherapy was proposed as follows

{du(t)dt=αu(t)(1−u(t)+w(t)K)−βu(t)v(t),dw(t)dt=βu(t)v(t)−δw(t),dv(t)dt=bδw(t)−βu(t)v(t)−γv(t). (2.1)

Here, u(t) stands for the uninfected tumor cell population at time t, w(t) stands for the infected tumor cell population, and v(t) stands for the free virus population. Tumor growth is modeled by logistic growth, and K is the maximum tumor population. The coefficient β represents infectivity of the virus. The infected tumor cells die with a rate δw. The parameter b is the burst size of the virus, the parameter γv is the clearance rate of free virus particles by various mechanisms including non-specific binding and generation of the defective interfering particles.

Viruses need time to complete their life cycle within cells. Incorporating the viral lytic cycle within infected tumor cells, in Wang et al [19], the following delay differential equation model was proposed.

{du(t)dt=αu(t)(1−u(t)+w(t)K)−βu(t)v(t),dw(t)dt=βu(t−τ)v(t−τ)−δw(t),dv(t)dt=bδw(t)−βu(t)v(t)−γv(t), (2.2)

where τ stands for the mean time period of the viral lytic cycle.

Now we assume that tumor cells diffuse with diffusion coefficient D1, and viruses diffuse with diffusion coefficient D2. It is an assumption to consider cell movement to only be by diffusion [38, 39]. Based on the mathematical models above, we propose a spatial mathematical model for oncolytic viral therapy as follows:

{∂u(x,t)∂t=D1Δu(x,t)+αu(x,t)(1−u(x,t)+w(x,t)K)−βu(x,t)v(x,t),∂w(x,t)∂t=D1Δw(x,t)+βu(x,t−τ)v(x,t−τ)−δw(x,t),∂v(x,t)∂t=D2Δv(x,t)+bδw(x,t)−βu(x,t)v(x,t)−γv(x,t), (2.3)

for which x ∈ Ω, t > 0, where Ω is the brain tissue which is a domain in ℝ3. To complete the model, we give the no-flux boundary conditions and initial conditions as follows:

{∂u(x,t)∂n=∂w(x,t)∂n=∂v(x,t)∂n=0,x∈∂Ω,t≥0;u(x,t)=u0(x,t)≥0,w(x,t)=w0(x,t)≥0,andv(x,t)=v0(x,t)≥0,x∈Ω¯,−τ≤t≤0. (2.4)

In the boundary and initial conditions, ∂Ω stands for the brain tissue boundary, n stands for its normal direction, Ω¯ stands for the brain tissue with it boundary, and u0(x, t), w0(x, t), v0(x, t) are initial densities. The zero-flux boundary condition means that there are no tumor cells or viruses crossing the brain tissue boundary. The zero-flux boundary condition for tumor cells has biological significance and has been applied in many diffusion type modeling of brain tumors [38, 39]. This is also biologically meaningful for viruses since oncolytic viruses do not infect normal cells by definition which are confined within the tumor [4].

We non-dimensionalize the system (2.3)–(2.4) by setting

t¯=δt,τ¯=δτ,u(x,t)=Ku¯(x,t¯),w(x,t)=Kw¯(x,t¯),v(x,t)=Kv¯(x,t¯),
r=αδ,a=βKδ,c=γδ,d1=D1δ,d2=D2δ,
u0(x,t)=Ku¯0(x,t¯),w0(x,t)=Kw¯0(x,t¯),v0(x,t)=Kv¯0(x,t¯).

For convenience, dropping all bars over the variables, we have

{∂u(x,t)∂t=d1Δu(x,t)+ru(x,t)(1−u(x,t)−w(x,t))−au(x,t)v(x,t),∂w(x,t)∂t=d1Δw(x,t)+au(x,t−τ)v(x,t−τ)−w(x,t),∂v(x,t)∂t=d2Δv(x,t)+bw(x,t)−au(x,t)v(x,t)−cv(x,t),x∈Ω,t>0;∂u(x,t)∂n=∂w(x,t)∂n=∂v(x,t)∂n=0,x∈∂Ω,t≥0;u(x,t)=u0(x,t)≥0,w(x,t)=w0(x,t)≥0,andv(x,t)=v0(x,t)≥0,x∈Ω¯,−τ≤t≤0. (2.5)

3. Analysis of the model

In this section, we study the properties of spatial homogenous equilibrium solutions and periodic solutions arising from Hopf bifurcations. The system (2.5) always has two spatially uniform steady states E0 = (0, 0, 0) and E1 = (1, 0, 0). When b>b0=1+ca, the system (2.5) has three spatially uniform steady states E0, E1 and E∗ = (u∗, w∗, v∗), where

u*=ca(b−1),w*=rc(ab−a−c)a(b−1)(rc+ab−a),v*=r(ab−a−c)a(rc+ab−a).

In Subsection 3.1, we establish positive invariant region as a sub-functional space for the ω limit sets of our model, and prove that the spatially uniform steady state E1 is globally asymptotically stable for any viral lytic period τ ≥ 0 when the viral burst size b < b0. In Subsection 3.2, we obtain the conditions, for example, the ratio of diffusion coefficients d2d1 is greater than some value and the viral lytic cycle is greater than a critical value, under which the spatially uniform positive steady state is locally asymptotically stable. We also obtain some conditions under which the system undergos Hopf bifurcations, and stable periodic solutions occur.

In what follows, we choose Ω be a open set in ℝ3, and define the real-valued Sobolev space

X={(u1,u2,u3)T∈(W2,2(Ω))3:∂u1∂n=∂u2∂n=∂u3∂n=0,atx∈∂Ω}.

3.1. Stability of the steady state of E1

To simplify notations, we denote u1(t) = u(x, t), u2(t) = w(x, t), u3(t) = v(x, t) and U(t) = (u1(t), u2(t), u3(t))T. Then, the system (2.5) can be rewritten as an abstract differential equation in the phase space C=C([−τ,0],X),

U˙(t)=DΔU(t)+G(Ut) (3.1)

where Ut(·) = U(t + ·), D = diag(d1, d1, d2) and G:C→X are defined by

G(Ut)=(ru1(t)(1−u1(t)−u2(t))−au1(t)u3(t)au1(t−τ)u3(t−τ)−u2(t)bu2(t)−au1(t)u3(t)−cu3(t)).

Let N be a operator satisfies

N(φt)(x)=∂φ(x,t)∂t−DΔφ(x,t)−G(φt)(x),

where φt(θ)(x) = φ(x, t + θ) = (φ1(x, t + θ), φ2(x, t + θ), φ3(x, t + θ)). Then N(0, 0, 0) = 0 ≤ 0 = N(ut, wt, vt)(x), where ut(θ)(x) = u(x, t + θ), wt(θ)(x) = w(x, t + θ), vt(θ)(x) = v(x, t + θ). Notices the homogeneous Neumann boundary and nonnegative initial value of system (2.5), we get (0, 0, 0) is a lower solution of system (2.5), and by the comparison principle we know that the solution (u, w, v) of system (2.5) satisfies u(x, t) ≥ 0, w(x, t) ≥ 0, v(x, t) ≥ 0 for t ≥ 0.

From the non-negativity of the solution, we have

∂u∂t≤d1Δu+ru(1−u).

The standard comparison theorem for parabolic boundary-value problems implies that u(x, t) ≤ U1(z, t) in Ω¯×[0,∞], where U1(x, t) is the positive solution of

{∂U1∂t=d1ΔU1+rU1(1−U1),x∈Ω,t>0,∂U1∂n=0,x∈∂Ω,t>0,U1(x,0)=u0(x,0)>0,x∈Ω¯.

It is well known that U1(x, t) → 1 as t → ∞. So we have limsupt→∞u(x,t)≤1. For any ε > 0, there exists a T1 > 0 such that u(x, t) ≤ 1 + ε in Ω¯×(T1,∞). When t > T1, we have

∂(u(x,t−τ)+w(x,t))∂t=d1Δ(u(x,t−τ)+w(x,t))+ru(x,t−τ)(1−u(x,t−τ)−w(x,t−τ))−w(x,t)≤d1Δ(u(x,t−τ)+w(x,t))+r(1+ε)(1−u(x,t−τ))−w(x,t)≤d1Δ(u(x,t−τ)+w(x,t))+r(1+ε)−r1(u(x,t−τ)+w(x,t))

where r1 = min{1, r}. Similar to the previous discussion and noticed the sufficiently small properties of ε, we get limsupt→∞(u(x,t−τ),w(x,t))≤rr1. Since u(x, t − τ) ≥ 0, we have limsupt→∞w(x,t)≤rr1. There exists a T2 > T1 + τ such that w(x,t)≤rr1+ε in Ω¯×(T2,∞). Then from the third equation of (2.5)

∂v(x,t)∂t≤d2Δv+bw(x,t)−cv(x,t)≤d2Δv+b(rr1+ε)−cv(x,t),t>T2.

Similar to the previous discussion, we get limsupt→∞≤brcr1.

We define C+=C(Ω¯×[−τ,0],ℝ+) with norm ‖φt‖=sup(x,θ)∈Ω¯×[−τ,0]φ(x,t+θ). From the pervious discussion, we have the following result.

Lemma 3.1.

The solution of the system (2.5) are ultimately uniformly bounded in C+×C+×C+.

The ω limit set of the system (2.5) is contained in the bounded region:

R={(ut,wt,vt)∈C+×C+×C+:‖ut‖≤1,‖wt‖≤rr1,‖vt‖≤brcr1}.

It is easy to verify that the region R is positively invariant for the system (2.5). In the rest of this paper, we will discuss the system (2.5) in region R.

From the above discussion, (u¯,w¯, v¯) is a upper solution when the initial value is in the domain R, where u¯,w¯, v¯ is the solution of the following system, respectively,

{∂u¯(x,t)∂t=d1Δu¯(x,t)+ru¯(x,t)(1−u¯(x,t)),x∈Ω,t>0;∂u¯(x,t)∂ν=0,x∈∂Ω,t≥0;u¯(x,t)=u0(x,t)≥0,x∈Ω¯,−τ≤t≤0,
{∂w¯(x,t)∂t=d1Δw¯(x,t)+abrcr1−w¯(x,t),x∈Ω,t>0;∂w¯(x,t)∂ν=0,x∈∂Ω,t≥0;w¯(x,t)=w0(x,t)≥0,x∈Ω¯,−τ≤t≤0,
{∂v¯(x,t)∂t=d2Δv¯(x,t)+brr1−cv¯(x,t),x∈Ω,t>0;∂v¯(x,t)∂ν=0,x∈∂Ω,t≥0;v¯(x,t)=v0(x,t)≥0,x∈Ω¯,−τ≤t≤0.

Furthermore, G(φ) satisfies a Lipschitz condition, therefore the system (2.5) has a unique classical solution when initial value is in the domain R.

Linearizing system (3.1) at E1, we have

U˙(t)=DΔU(t)+LE1(Ut), (3.2)

where

LE1(Ut)=(−r−r−a0−100b−a−c)(u1(t)u2(t)u3(t))+(00000a000)(u1(t−τ)u2(t−τ)u3(t−τ)).

From Wu [37], the corresponding integral equation of (3.1) is

U(t)=T(t)U(0)+∫0tT(t−s)LE1(Us)ds, (3.3)

where T(t) is a C0 semigroup generated by DΔ. And its characteristic equation is given by

λy−DΔy−LE1(eλ⋅y)=0, (3.4)

where y ∈ dom(Δ) \ {0}, dom(Δ) ⊂ X and eλ·(θ)y = eλθy, for θ ∈ [−τ, 0]. It is known that the eigenvalue problem

{−Δϕ=μϕ,x∈Ω,∂ϕ∂n=0,x∈∂Ω,

has eigenvalues μn, n∈ℕ0=ℕ∪{0}, with corresponding eigenfunctions φn(x), and μn satisfy 0 = μ0 < μ1 ≤ μ2 ≤ ··· ≤ μn ≤ ···. By using the Fourier expansion in (3.4),

y=∑n=0∞(anbncn)ϕn(x),

where an, bn, cn∈ℂ, we know that the characteristic equation (3.4) is equivalent to

det(λ+d1μn+rra0λ+d1μn+1−ae−λτ0−bλ+d2μn+a+c)=0,n∈ℕ0.

That is, each eigenvalue λ is a root of the equation

(λ+d1μn+r)(λ2+Tnλ+Dn−abe−λτ)=0,n∈ℕ0, (3.5)

where Tn = (d1 + d2)μn + a + c + 1,Dn=d1d2μn2+[d1(a+c)+d2]μn+a+c. By discussing the distribution of the roots of (3.5), we have the following Lemma.

Lemma 3.2.

E1 is locally asymptotically stable when b<1+ca. E1 is unstable when b>1+ca.

Proof.

Obviously, λ1,n = −d1μn − r < 0, n∈ℕ0, are roots of (3.5). We only need to discuss the roots of

λ2+Tnλ+Dn−abe−λτ=0,n∈ℕ0. (3.6)

When τ = 0, noticed that Tn2−4(Dn−ab)=(d1−d2)2μn2+2(a+c+1)(d1+d2)μn+(a+c−1)2+4ab>0, we get equation (3.6) has two series real roots

λ2,n=−12Tn−12Tn2−4(Dn−ab),n∈ℕ0,
λ3,n=−12Tn+12Tn2−4(Dn−ab),n∈ℕ0.

Clearly, λ2,n < 0 for n∈ℕ0. And λ3,n < 0 for all n∈ℕ0 if and only if b<1+ca. We claimed that all the roots have negative real parts when b<1+ca and τ > 0. Otherwise, we assume (3.6) have a pure imaginary root iνn for some τ > 0, then we have

−νn2+iTnνn+Dn−ab(cosνnτ−isinνnτ)=0.

Separating the real and imaginary parts gives

{−ν2+Dn=abcosνnτ,−Tnνn=absinνnτ.

Furthermore, we need

νn4+(Tn2−2Dn)νn2+Dn2−a2b2=0. (3.7)

Denote Qn(z)=z2+(Tn2−2Dn)z+Dn2−a2b2. Obviously,

Tn2−2Dn=(d12+d22)μn2+[2d1+2(a+c)d2]μn+(a+c)2+1>0.

If b<1+ca, then

Dn2−a2b2={d1d2μn2+[d1(a+c)+d2]μn}2+2(a+c){d1d2μn2+[d1(a+c)+d2]μn}+(a+c)2−a2b2>0.

So Qn(z) has no positive roots when b<1+ca. We know that (3.7) is always not valid when b<1+ca. This is a contradiction. □

Remark 3.3.

The spatially uniform steady state E0 of the system (2.5) is always unstable because there has an eigenvalue r > 0.

Theorem 3.4.

If b<b0=1+ca, then the spatially uniform steady state E1 of the system (2.5) is globally asymptotically stable for τ ≥ 0.

Proof.

Define a Lyapunov functional on the region R by

V(ϕt)(x)=∫Ω(bφt2(x,0)+φt3(x,0)+ba∫−τ0φt1(x,θ)φt3(x,θ)dθ)dx

where ϕt(θ)=(φt1(θ),φt2(θ),φt3(θ)), φti(θ)(x)=φi(x,t+θ), i = 1, 2, 3. When b < b0, by virtue of the Neumann boundary condition, we obtain that

V˙(ϕt)=∫Ω[a(b−1)φt1(x,0)−c]φt3(x,0)dx≤∫Ω[a(b−1)−c]φt3(x,0)dx≤0.

And V˙(ϕt)=0 if and only if φt3(x,0)=0. Furthermore, we can get the maximum invariant set in {φ ∈ R : V˙(ϕt)=0} is the single point set {E1}. The Lasalles invariance principle implies that E1 is globally attractive. By Lemma 3.2, we get E1 is global asymptotically stable for τ ≥ 0. □

3.2. Stability of the positive steady state E∗ and Hopf bifurcations

If b>b0=1+ca, the system (2.5) has a spatially uniform positive steady state E∗. In this subsection, we always assume that b>b0=1+ca holds.

Linearizing the system (2.5) at E∗, we get

U˙(t)=DΔU(t)+LE*(Ut),

where

LE*=L1ϕ(0)+L2ϕ(−τ)

with

L1=(−ru*−ru*−au*0−10−av*b−au*−c)andL2=(000av*0au*000),

for φ(θ) = (φ1(θ), φ2(θ), φ3(θ))T. Similar to the previous subsection, we find that the characteristic equation is equivalent to

λ3+a2,nλ2+a1,nλ+a0,n+(b1,nλ+b0,n)e−λτ=0,n∈ℕ0, (3.8)

where

a2,n=(2d1+d2)μn+rc+abc+ab−aa(b−1),
a1,n=(d12+2d1d2)μn2+[rc+2abc+a2b−a2a(b−1)d1+rc+ab−aa(b−1)d2]μn+rc(bc+b−1)a(b−1)2+bcb−1−rc(ab−a−c)(b−1)(rc+ab−a),
a0,n=d12d2μn3+[bcb−1d12+rc+ab−aa(b−1)d1d2]μn2+[(bc(rc+ab−a)a(b−1)2−rc(ab−a−c)a(b−1)(rc+ab−a))d1+rca(b−1)d2]μn+rbc2a(b−1)2−rc(ab−a−c)(b−1)(rc+ab−a),
b1,n=r2c(ab−a−c)(b−1)(rc+ab−a)−bcb−1,
b0,n=[r2c(ab−a−c)a(b−1)(rc+ab−a)d2−bcb−1d1]μn−rbc2a(b−1)2+rc(ab−a−c)(ab+rc)a(b−1)(rc+ab−a).

When τ = 0, the characteristic equation (3.8) becomes the following sequence of equations

λ3+a2,nλ2+(a1,n+b1,n)λ+a0,n+b0,n=0,n∈ℕ0. (3.9)

By the Routh-Hurwitz Criterion, all roots of (3.9) have negative real parts if and only if

H1,n=a2,n>0,H2,n=a2,n(a1,n+b1,n)−a0,n−b0,n>0,H3,n=(a0,n+b0,n)H2,n>0

for n∈ℕ0. When b > b0, we can see that a2,n > 0 and a0,n + b0,n > 0 for n∈ℕ0. So when

(H)b>b0,a2,n(a1,n+b1,n)−a0,n−b0,n>0,

all roots of (3.9) have negative real parts. We get the following conclusion.

Lemma 3.5.

If (H) holds, the spatially uniform positive steady state E∗ of the system (2.5) is locally asymptotically stable when τ = 0.

Now we look for sufficient conditions to ensure H2,n > 0. By calculation, we have

H2,n=2d1(d1+d2)2μn3+A3μn2+(A1d1+A2d2)μn+H2,0

where

A1=(rc+abc+ab−a)(a2b−a2+2abc+rc)a2(b−1)2+rc[2c(rc+ab)+(b−1)(3a+2ra−a2)+c]a(b−1)(rc+ab−a)−rc(b−2c)a(b−1)2,
A2=(rc+abc+ab−a)(rc+ab−a)a2(b−1)2+rbc2a(b−1)2−rc(ab−a−c)a(b−1)(rc+ab−a),
A3=[4abc+3rca(b−1)+2a+1]d12+rc+ab−aa(b−1)d22+[4rc+2ac+2abca(b−1)+2c+a+3]d1d2,
H2,0=rc(rc+abc+ab−a)a2(b−1)2[rc(bc+b−1)(b−1)+(ab−a−c)(r−a)rc+ab−a]−rc(ab−a−c)a(b−1).

If b > b0, then A3 > 0. We define a function ψ(x) by

ψ(x)=−a3x4+[c3+3c+r+1−(c−1)a3]x3+[(c2+3c+r+1)rca−3(2c+r+1)a2−(3−2c)a3]x2+[r2c3−(3c+2r+2)rca−(c2−3c−3r−3)a2−(c−1)a3]x+rc(r+1)a−(r+1)a2.

It is easy to see that

H2,0=rcψ(b)a(b−1)3(rc+ab−a).

When b > b0, sign{H2,0} = sign{ψ(b)}. Since

ψ(b0)=c3(r+1)[r+a+2c+2+(c+1)(r+c+1)a]>0

and ψ(x) → −∞ as x → ±∞, so ψ(x) has at least one root and at most three root greater than b0. According to the distribution of the roots of ψ(x), we have the following two cases:

Case I: ψ(b) has only root b1 > b0 or has three roots b1, b2, b3 which are greater than b0. When it has three roots which greater than b0, the three roots are satisfied b1 < b2 = b3 or b1 = b2 = b3.

Case II: ψ(b) has three roots b1, b2, b3 that are greater than b0, and the three roots are satisfied b1 ≤ b2 < b3.

When Case I occurs, if b ∈ (b0, b1), then H2,0 > 0. When Case II occurs, if b∈(b0,b1)∪(b2,b3), then H2,0 > 0.

When b > b0, we can see that A3 > 0. So if b > b0, H2,0 > 0 and A1d1 +A2d2 ≥ 0, then H2,n > 0 for n∈ℕ0.

When A2 > 0, if the diffusion coefficient d2 is sufficiently large relative to the diffusion coefficient d1, then A1d1 + A2d2 ≥ 0 can be established.

It is easy to see that if rbc2a(b−1)2−rc(ab−a−c)a(b−1)(rc+ab−a)>0, then A2 > 0.rbc2a(b−1)2−rc(ab−a−c)a(b−1)(rc+ab−a)>0, is equivalent to

a(c−a)b2+(rc2+2a2)b−a(c+a)>0. (3.10)

When c = a, the (3.10) always holds since b > b0. When c ≠ a, the equation a(c − a)b2 + (rc2 + 2a2)b − a(c + a) = 0 has two real roots

b4,5=−(rc+2a2)±r2c2+4ra2+4a22a(c−a).

If c > a, b5 < 0 < b4 and the (3.10) holds when b > b4 or b < b5. If c < a, 0 < b4 < b5 and the (3.10) holds when b4 < b < b5.

Through calculation, we get A2=a3y3+a2y2+a1y+a0a2y2(ay+rc), where

a0=(r+2a)c3r2>0,
a1=(3r+2cr+4a)ac2r>0,
a2=[(1−r)a+3(c+1)r]a2c,
a3=(c+1)a3>0,
y=b−1.

If r ≤ 1 or a ≤ 3(c + 1), then a2 > 0. When r > 1 and a > 3(c + 1), a2 > 0 if and only if r<aa−3(c+1). Obviously, if a2 > 0, then A2 > 0 for b > b0.

From the discussion above and Lemma 3.5, we reach the following conclusions.

Corollary 3.6.

In Case I, if one of the following conditions holds

  1. c > a, max{b0, b4} < b < b1,

  2. c < a, max{b0, b4} < b < min{b1, b5},

  3. c = a, b0 < b < b1,

and d2d1>−A1A2, then the spatially uniform positive steady state E∗ of the system (2.5) is locally asymptotically stable when τ = 0.

Corollary 3.7.

In CaseII, if one of the following conditions holds

  1. c > a, max{b0, b4} < b < b1 or max{b2, b4} < b < b3,

  2. c < a, max{b0, b4} < b < min{b1, b5} or max{b2, b4} < b < min{b3, b5},

  3. c = a, b0 < b < b1 or b2 < b < b3,

and d2d1>−A1A2, then the spatially uniform positive steady state E∗ of system (2.5) is locally asymptotically stable when τ = 0.

Corollary 3.8.

Suppose b > b 0 . If one of the following conditions holds

  1. r ≤ 1,

  2. a ≤ 3(c + 1),

  3. a > 3(c + 1) and 1<r<aa−3(c+1)

and d2d1>−A1A2, then the spatially uniform positive steady state E∗ of system (2.5) is locally asymptotically stable when τ = 0.

Now, we assume the condition (H) holds. we would like to seek critical value τ such that there exists a pair of purely imaginary eigenvalue. Let iω(ω > 0) be the solution of the (n + 1)th equation of (3.8), we have

−iω3−a2,nω2+ia1,nω+a0,n+(ib1,nω+b0,n)(cosωτ−isinωτ)=0.

Separating the real and imaginary parts gives

{−ω3+a1,nω=b0,nsinωτ−b1,nωcosωτ,a2,nω2−a0,n=b0,ncosωτ+b1,nωsinωτ. (3.11)

Square each sides of (3.11) and plus, we have

ω6+fnω4+gnω2+hn=0 (3.12)

where fn=a2,n2−2a1,n, gn=a1,n2−2a2,na0,n−b1,n2,hn=a0,n2−b0,n2.

Let z = ω2, then (3.12) becomes

Pn(z)=z3+fnz2+gnz+hn=0. (3.13)

Lemma 3.9.

For the equation (3.13), we have the following conclusions.

  1. If hn < 0, the equation (3.13) has at least one positive roots.

  2. If hn ≥ 0 and fn2−3gn≤0, the equation (3.13) has no positive root.

  3. If hn ≥ 0 and fn2−3gn>0, the equation (3.13) has positive roots if and only if z1,n*>0 and P(z1,n*)≤0, where z1,n*=−fn+fn2−3gn3.

Proof.

Since Pn(z) → +∞ as z → +∞, we conclude that Pn(z) has at least one positive root if Pn(0) = hn < 0. Differentiating Pn(z) with respect to z, we have Pn′(z)=3z2+2fnz+gn. If fn2−3gn≤0, then Pn′(z)≥0 and Pn(z) is nondecreasing when z ≥ 0. Thus for hn ≥ 0 and fn2−3gn≤0, the equation (3.13) has no positive root. When hn ≥ 0 and fn2−3gn>0, Pn′(z) has two roots z1,n*=−fn+fn2−3gn3 and z2,n*=−fn−fn2−3gn3. Clearly,

pn′′(z1,n*)=2fn2−3gn>0,pn′′(z2,n*)=−2fn2−3gn<0.

So z1,n* is the locally minimum point of Pn(z) and z2,n* is the locally maximum point of Pn(z). Noticing that hn ≥ 0, z1,n* is the local minimum of Pn(z) and Pn(z) → +∞ as z → +∞, we know that the sufficiency of (iii) is true. In what follows, we need to prove the necessity of (iii). Suppose that either z1,n*≤0 or z1,n*>0 and Pn(z1,n*)>0. Since Pn(z) is increasing for z ≥ 0 and Pn(0) = hn ≥ 0, we know that Pn(z) has no positive real roots for z1,n*≤0. If z1,n*>0 and Pn(z1,n*)>0, since h(x1*) is the local minimum value, it follows that Pn(0) = hn > 0 that when z1,n* and Pn(z1,n*)>0, Pn(z) has no positive real roots, too. This proves the lemma. □

Corollary 3.10.

If b0<b<b6=1+3c2a+9c2+8ac2a, then h0 < 0.

Proof.

When b > b0, we have a0,0 + b0,0 > 0. So h0=a0,02−b0,02=(a0,0+b0,0)(a0,0−b0,0)<0 if a0,0 − b0,0 < 0 and b > b0.

a0,0−b0,0=2rbc2a(b−1)2−rc(ab−a−c)(ab+rc+a)(b−1)(rc+ab−a)=rca(b−1)(2bcb−1−(ab−a−c)−2a(ab−a−c)rc+ab−a)

If b > b0 and 2bcb−1−(ab−a−c)<0, then a0,0 − b0,0 < 0. When b > b0,

2bcb−1−(ab−a−c)<0
⇔ab2−(2a+3c)b+a+c>0
⇔1+3c2a−9c2+8ac2a<b<1+3c2a+9c2+8ac2a.

Because of 1+3c2a−9c2+8ac2a<b0<1+3c2a+9c2+8ac2a, we get h < 0 if b0 < b < b6. □

Denote

D={n∈ℕ0:hn<0;orhn≥0,fn2−3gn>0,z1,n*0,andPn(z1,n*)≤0}.

From Lemma 3.9, we know that the equation (3.13) has positive roots if and only if n∈D. Without loss of generality, we assume the equation (3.13) has three positive roots z1,n, z1,n and z3,n when n∈D. We denote ωk,n=zk,n and

τk,n(j)={1ωk,n[arccosb0,n(a2,nωk,n2−a0,n)+b1,nωk,n(ωk,n2−a1,nωk,n)b1,n2ω+k,n2+b0,n2+2jπ],sinωk,nτk,n(0)≥0,1ωk,n[−arccosb0,n(a2,nωk,n2−a0,n)+b1,nωk,n(ωk,n2−a1,nωk,n)b1,n2ω+k,n2+b0,n2+2(j+1)π],sinωk,nτk,n(0)<0,

for k = 1, 2, 3, j∈ℕ0 and n∈D. When τ=τk,n(j), the equation (3.8) has a pair of purely imaginary roots ±iωk,n.

For some n∈D, let λ(τ) = αn(τ) + iω be a root of the (n + 1)th equation of (3.8) which satisfies ωn(τk,n(j))=ωk,n and αn(τk,n(j))=0 for k = 1, 2, 3 and j∈ℕ0.

Lemma 3.11.

sign{αn′(τk,n(j))}=sign{Pn′(zk,n)}
Proof.

Differentiating the both side of the equation (3.8) with respect to τ, it follows that

(dλdτ)−1=(3λ2+2a2,nλ+a1,n)eλτλ(b1,nλ+b0,n)+b1,nλ(b1,0λ+b0,n)−τλ.

From (3.11), we have

αn′(τk,n(j))−1=Re(dλdτ)−1|τ=τk,n(j)=Pn′(zk,n)b1,n2ωk,n2+b0,n2.

This proves the lemma. □

Let

τ*=τk0,n0(0)=mink=1,2,3,n∈D{τk,n(0)}.

From Lemma 3.5, 3.9 and 3.11, we have the following conclusion.

Theorem 3.12.

Suppose the condition (H) holds.

  1. If h ≥ 0, fn2−3gn≤0, or fn2−3gn>0, z1,n*<0, or fn2−3gn>0, z1,n*>0, Pn(z1,n*)>0 for all n∈ℕ0, the spatially uniform steady state E∗ of the system (2.5) is locally asymptotically stable for all τ > 0.

  2. If hn < 0, or hn ≥ 0, fn2−3gn>0, z1,n*>0 and Pn(z1,n*)≤0 for some n∈ℕ0, the spatially uniform steady state E∗ of the system (2.5) is locally asymptotically stable for τ ∈ [0, τ∗).

  3. If all conditions as stated in (ii) and Pn′(zk,n)≠0 hold, the system (2.5) undergoes a Hopf bifurcation at E∗ when τ=τk,n(j), k = 1, 2, 3,j∈ℕ0.

4. Numerical simulations

For the convenience of presentation, our numerical simulations are performed for the tumor site as a domain in ℝ2. We describe briefly the numerical method we use to solve the system (2.5) at the end of the appendix. In the following, we demonstrate several typical cases which correspond to our analysis.

Let Ω = (0, π) × (0, π) (i.e. p = q = 1), and choose

r=0.1,a=0.01,c=0.08,d1=0.02,d2=0.2.

For this set of parameter values we can get b0=1+ca=9, b1 ≈ 135.5540. And when 9 < b < 135.5540, (H) holds. So when τ = 0, the positive steady state E∗ is stable if 9 < b < 135.5540. From our calculation, we find only for b ≥ 24.4105 and n = 0, (3.12) has a positive root, and we get a bifurcation curve about τ∗ and b (see Figure 1).

Figure 1:

Figure 1:

A bifurcation curve τ∗(b).

If we choose

r=0.1,a=0.01,b=4,c=0.08,d1=0.02,d2=0.2,τ=2.

For this set of parameter values we observe that b<1+ca. So from Theorem 3.4, the steady stete E1 = (1, 0, 0) is globally asymptotically stable (see Figure 2). The initial conditions of Figure 3 are u(x, t) = 0.5000 + 0.3000 cos 2x cos y, w(x, t) = 0.0500 + 0.0300 cos 2x cos y, v(x, t) = 8.0000 + 2.0000 cos 2x cos y, (x, y, t) ∈ [0, π] × [0, π] × [−τ, 0]. In Figure 2, we take x = π/3 and y = π/3 respectively.

Figure 2:

Figure 2:

The steady stete E1 = (1, 0, 0) is globally asymptotically stable.

Figure 3:

Figure 3:

The positive equilibrium is asymptotically stable when τ ∈ [0, τ∗), where τ = 0.9 < τ∗ ≈ 1.8518.

If we chose b = 60, then by calculation, we have

ω1,0=≈0.0743,τ1,0(j)+≈1.8518+84.5804j,forj∈ℕ0.

So τ*=τ1,0(0)≈1.8518. Furthermore, from Appendix A, we have c1(0) ≈ ≈ −0.5369 − 2.2209i,P′(ω1,02)=0.0118>0. From Theorem 3.12 and Appendix A, we know that positive equilibrium E∗ = (0.1356, 0.0116, 8.5284) is locally asymptotically stable when τ ∈ [0, τ∗) (see Figure 3), and the direction of the Hopf bifurcation is supercritical when τ = τ∗, that is the bifurcating periodic solutions exist for τ > τ∗, and they are orbitally stable(see Figure 4). The initial conditions of Figure 3 are u(x, t) = 0.1356 + 0.1000 cos 2x cos y, w(x, t) = 0.0116 + 0.0100 cos 2x cos y, v(x, t) = 8.5284 + 3.0000 cos 2x cos y, (x, y, t) ∈ [0, π]×[0, π]×[−τ, 0] and the initial conditions of Figure 4 are u(x, t) = 0.2000 + 0.1000 cos 2x cos y, w(x, t) = 0.0200 + 0.0100 cos 2x cos y, v(x, t) = 8.5000 + 3.0000 cos 2x cos y, (x, y, t) ∈ [0, π] × [0, π] × [−τ, 0]. In Figure 3 and Figure 3, we take x = π/3 and y = π/3 respectively.

Figure 4:

Figure 4:

The bifurcating periodic solution is stable, where τ = 2 > τ∗ ≈ 1.8518.

5. Conclusion and discussion

Incorporating virus diffusivity, tumor cell diffusion, and the viral lytic cycle into a basic oncolytic virus dynamics model, we formulate a mathematical model in terms of delay partial differential equations for oncolytic virotherapy. We conduct a detailed study of the dynamics of our model. We find the positive invariant domain for the omega limit set and three spatially uniform equilibrium solutions of our model. Comparing with the basic models without diffusions of virus and tumor cells and the delay of the viral lytic cycle, we find a first critical value of the viral burst size, and when the viral burst size is smaller than this first critical value, the spatially uniform virus-free steady state is globally asymptotically stable for any viral lytic period delay and any diffusion coefficients of tumor cells and viruses. When the viral burst size is greater than the first critical value, we characterize the stability of the spatially uniform positive steady state by three major parameters: the ratio of virus diffusion coefficient to that of tumor cells, the length of the viral lytic cycle, and the viral burst size with six different values that are greater than the first critical value. These results are summarized in Lemma 3.5 with Corollaries 3.6, 3.7, and 3.8; lemma 3.9 with Corollary 3.10, Lemma 3.11; and Theorem 3.12. These detailed information cannot be obtained from the models without diffusions of virus and tumor cells and delays of viral lytic cycle. For instant, if we don’t consider the viral lytic cycle meaning the viral lytic cycle length is zero, in order to have a locally asymptotical stability of the spatially uniform positive steady state, the ratio between diffusion coefficients must be greater than a particular value and the viral burst size must be greater than the first critical value but smaller than other values depending on the tumor growth rate and virus clearance rate. If we consider the viral lytic cycle as a delay parameter, we find a critical value for the length of the viral lytic cycle. Combining conditions for the ratio between diffusion coefficients and viral burst size, the spatially uniform positive steady state is locally asymptotical stable when the viral lytic cycle length is smaller than the critical value while the system undergoes Hopf bifurcation at the critical value of the viral lytic cycle length and has stable periodic solutions when the viral lytic cycle length is greater than the critical value. For these results, we give some biological implications as follows.

From our analysis, we know that the parameters including the viral burst size, the viral lytic cycle, the diffusion coefficients of viruses and cells play important roles in the dynamics of oncolytic viral therapy. Our model has three spatially homogeneous equilibrium solutions, E0, E1, and E∗ which are related to long-term behaviors of general solutions. They may have some medical implications. It is reasonable that the zero solution E0 is always unstable for any parameter values since the tumor always grows in its beginning. Theorem 3.4 gives a critical value for the viral burst size, and below that value, the viral therapy fails no matter what values of any other parameters are chosen. This confirms that the potency of oncolytic viruses is important, and the viral burst size greater than that critical value is necessary condition for the treatment to work. It is hoped oncolytic viruses will eradicate the tumor completely. However, this is not always the case. When viruses cannot completely eradicate the tumor, we may hope the virus treatment will be stabilized at a level where the tumor cells, infected tumor cells, and viruses are constant. We find some conditions under which the viral therapy can be stabilized. Under the condition (H) which includes the viral burst size is greater than the critical value and the ratio of virus diffusion coefficient to cell diffusion coefficient is greater than certain values in Corollary 3.6–3.8, and the condition states in Theorem 3.12, the spatially uniform equilibrium solution E∗ which is constant solution is stable. We also obtain a critical value of the viral lytic cycle below that value E∗ is stable while at that value point, the system undergoes a Hopf bifurcation. Spatially homogeneous periodic solutions arise from Hopf bifurcations. We numerically show these periodic solutions are stable. We may consider the stable spatially homogeneous periodic solution as one type of treatment stabilization. In addition, we find a functional relationship between the viral burst size and lytic cycle shown in Figure 1 which may implicate that the viral lytic cycle length will change if the viral burst size changes. Since we can genetically change viral genome for different burst sizes, we accordingly change their lytic cycles. As long as the condition in Theorem 3.12 is satisfied, the stabilization of treatments can be achieved.

As mentioned in Introduction, there have been many studies on oncolytic virotherapy experimentally and theoretically. Recently, Wodarz et al [29] conducted an in vitro experiment with recombinant adenovirus type-5 in a two-dimensional setting and used an agent-based stochastic computational model to simulate experimental observations. They observed three spatial patterns, “hollow ring structure”, “filled ring structure”, and “disperse pattern”. They found that both the filled ring structure and disperse pattern of initial expansion were indicative of treatment failure. The hollow ring structure was associated with either target cell extinction or low-level persistence, both of which can be viewed as treatment success. It seems that the filled ring structure and disperse pattern correspond to the spatial positive steady state in our model, and the hollow ring structure corresponds the spatial virus-free steady state in our model. However, our study gives more detailed information about the spatial positive equilibriums and possibilities of stable periodic behaviors of the spatial patterns. They also found that equilibrium properties of ordinary differential equations describing the dynamics in local neighborhoods in the agent-based model can predict the outcome of the spatial virus-cell dynamics. This finding agrees with our results since our model is based on local interactions. A more recent study by Wang et al [30] incorporated nonlocal reaction terms in their delay reaction-diffusion system for oncolytic virotherapy. They gave different treatment strategies according to different gene mutations, which has theoretical interests. Friedman and Lai [31] presented a computational study about combination therapy for cancer with oncolytic virus and checkpoint inhibitor. This study did not focus on spatial patterns of oncolytic virus spreading within tumors. Timalsina et al [32] proposed a detailed reaction-diffusion model for virotherapy and conducted a computational study. This model focused on the different functions of innate and adaptive immune systems in oncolytic viral therapies.

It is clear that our model incorporates basic components of oncolytic viral therapy although it reveals important features of oncolytic viral therapy. There are several components which are not included, for example, immune cells. The immune system has two different functions in oncolytic viral therapies. The immune cells can be incorporated to our model. However, it is beyond the scope of our current work. This may be considered in our future study.

Acknowledgment

JZ and JPT would like to acknowledge the support from U54CA132383 of NIH (awarded to JPT), Fundamental Research Funds for the Universities in Heilongjiang Province(No: RCCX201718, awarded to JZ) and Fundamental Research Funds of Education Department of Heilongjiang Province(No: 135109228, awarded to JZ). The authors would like to acknowledge the suggestion of model formulation from Philip K. Maini. The authors would like to thank two anonymous reviewers for their insightful comments and constructive suggestions which greatly help in improving the presentation of our results.

A. Stability and direction of the Hopf bifurcations

Theory of functional reaction-diffusion systems says that a family of spatially homogeneous or inhomogeneous periodic solutions may bifurcate from the positive homogeneous equilibrium state E∗ of the system (2.5) when τ crosses through the critical value τ∗. In Appendix, we investigate the stability and direction of Hopf bifurcations by using the center manifold theorem and the normal formal theory of partial functional differential equation [34, 37]. Basically, the system (2.5) firstly is represented as an abstract ODE system. Secondly, at the center manifold of the ODE system corresponding to E∗, the normal form or Taylor expansion of the ODE system is computed. Then, the coefficients of the first 4 terms of the normal form will reveal all the properties of the periodical solutions [35]. At the end, we briefly describe the numerical method we use to solve our system.

Let u1(·, t) = u(·, τt) − u∗, u2(·, t) = w(·, τt) − w∗, u3(·, t) = v(·, τt) − v∗ and U(t) = (u1(·, t), u2(·, t), u3(·, t))T. Then the system (2.5) can be written as an equation in the function space C=C([−1,0],X) :

dU(t)dt=τDΔU(t)+L(τ)(Ut)+f(Ut,τ), (A.1)

where D = diag(d1, d1, d2), L(τ)(⋅):C→X and f:C×ℝ→X are given, respectively, by

L(τ)(φ)=τL1φ(0)+τL2φ(−1),
f(φ,τ)=τ(f1(φ,τ),f2(φ,τ),f3(φ,τ))T,

with

f1(φ,τ)=−rφ12(0)−rφ1(0)φ2(0)−aφ1(0)φ3(0),
f2(φ,τ)=aφ1(−τ)φ3(−τ),
f3(φ,τ)=−aφ1(0)φ3(0),

for φ=(φ1,φ2,φ3)T∈C. Let τ = τ∗ + σ, then (A.1) can be rewritten as

dU(t)dt=τ*DΔU(t)+L(τ*)(Ut)+F(Ut,σ), (A.2)

where

F(φ,σ)=σDΔφ(0)+L(σ)(φ)+f(φ,τ*+σ),

for φ∈C.

From the previous subsection, when σ = 0 (i.e. τ = τ∗) the system (A.2) undergoes Hopf bifurcation at the equilibrium (0, 0, 0). It is also clear that ±iω∗τ∗ are simply purely imaginary eigenvalues of the linearized system of (A.2) at the origin

dU(t)dt=(τ*+σ)DΔU(t)+L(τ*+σ)(Ut), (A.3)

with σ = 0 and all other eigenvalues of (A.3) at σ = 0 have negative real parts.

The eigenvalues of τDΔ on X are −τd1μn (the number of multiples is two) and −τd2μn, n∈ℕ0, with corresponding eigenfunctions βn1(x)=(γn(x),0,0)T, βn2(x)=(0,γn(x),0)T and βn3(x)=(0,0,γn(x))T, where γn(x)=ϕn(x)(∫ωϕn(x)dx)12.

We have that the solution operator of (A.3) is a C0 semigroup, and the infinitesimal generator Aσ is given by

Aσϕ={ϕ˙(θ),θ∈[−r,0),DΔϕ(0)+L(τ*+σ)(ϕ),θ=0. (A.4)

and the domain dom(Aσ) of Aσ is

dom(Aσ):={ϕ∈C:ϕ˙∈C,ϕ(0)∈dom(Δ),ϕ˙(0)=DΔϕ(0)+L(τ*+σ)(ϕ)},

Hence, equation (A.2) can be rewritten as the abstract ODE in C:

U˙t=AσUt+R(σ,Ut), (A.5)

where

R(σ,Ut)(θ)={0,θ∈[−1,0),F(σ,Ut),θ=0.

We denote

βn={(1,0,0)Tγn,(0,1,0)Tγn,(0,0,1)Tγn}.

For ϕ=(ϕ(1),ϕ(2))T∈C, denote

ϕn=〈ϕ,βn〉=(〈ϕ(1),γn〉,〈ϕ(2),γn〉,〈ϕ(3),γn〉)T.

Define Aσ,n as

Aσ,n(ϕn(θ)γn)={ϕ˙n(θ)γn,θ∈[−1,0),∫−r0dηn(σ,θ)ϕn(θ)γn,θ=0. (A.6)

Furthermore, we have

Lσ,n(ϕn)=(τ*+σ)L1ϕn(0)+(τ*+σ)L2ϕn(−1),

and

−μnDϕn(0)+Lσ,n(ϕn)=∫−10dηn(σ,θ)ϕn(θ),

where

ηn(σ,θ)={−(τ*+σ)L2,θ=−1,0,θ∈(−1,0),(τ*+σ)(L1−μnD),θ=0.

Define C*=C([0,1];X) and a bilinear form (·,·) on C*×C

(ψ,ϕ)=∑k,j=0∞(ψk,ϕj)c∫Ωγkγjdx,

where (·, ·)c is the bilinear form defined on C∗ × C

(ψn,ϕn)c=ψ¯nT(0)ϕn(0)−∫−10∫ξ=0θψ¯nT(ξ−θ)dηn(0,θ)ϕn(ξ)dξ,

and

ψ=∑n=0∞ψnγn∈C*,ϕ=∑n=0∞ϕnγn∈C,

with

ϕn∈C=C([−1,0],ℝ2),ψn∈C*=([0,1],ℝ2).

Notice that

∫Ωγkγjdx=0fork≠j,

we have

(ψ,ϕ)=∑n=0∞(ψn,ϕn)c,

We define the adjoint operator A∗ of A0

A*ψ(s)={−ψ˙(s),s∈(0,1],∑n=0∞∫−10dηnT(0,t)ψn(−t)γn,s=0.

Let

q(θ)γn0=q(0)eiω*τ*θγn0,q*(s)γn0=q*(0)eiω*τ*sγn0

be the eigenfunctions of A0, and A∗ corresponds to iω∗τ∗ and −iω∗τ∗, respectively. By direct calculations, we chose

q(0)=(1,C1,C2)T,q*(0)=M(1,C3,C4)T

where

C1=a2u*v*−(iω*+d1μn0+ru*)(iω*+d2μn0+au*+c)abu*+ru*(iω*+d2μn0+au*+c),
C2=−(iω*+d1μn0+ru*)b+rau*v*abu*+ru*(iω*+d2μn0+au*+c),
C3=(−iω*+d1μn0+ru*)(−iω*+d2μn0+au*+c)−a2u*v*av*e−iω*τ*(−iω*+d2μn0+c),
C4=(−iω*+d1μn0+ru*)u*−au*v*v*(−iω*+d2μn0+c)

and

M¯=11+C1C3¯+C2C4¯+τ*aC3¯(v*+u*C2)e−iωτ*.

Obviously, (q∗, q)c = 1. Then we decompose C by

Λ={±iω*τ*},

C=P⊕Q, where

P={zqγn0+zq¯γn0∣z∈ℂ},
Q={ϕ∈C∣(q*γn0,ϕ)=0and(q¯*γn0,ϕ)=0}.

Thus, system (A.5) could be rewritten as

Ut=z(t)q(⋅)γn0+z¯(t)q¯(⋅)γn0+W(t,⋅),

where

W(t,⋅)∈Q.

As in [35], we have

z(t)=(q*γn0,Ut),W(t,θ)=Ut(θ)−2Re{z(t)q(θ)γn0}. (A.7)

Then it follows that

z˙(t)=iω0z(t)+q¯*T(0)〈F(0,Ut),βn0〉, (A.8)

where

〈F,βn〉:=(〈F1,γn〉,〈F2,γn〉,〈F3,γn〉)T,

With the center manifold theorem [36], there exists a center manifold C0 and on C0 we have

W(t,θ)=W(z(t),z¯(t),θ)=W20(θ)z22+W11(θ)zz¯+W02(θ)z¯22+⋯, (A.9)

where z and z¯ are local coordinates for center manifold C0 in the direction of qγn0 and q¯γn0, respectively. For solution Ut∈C0, we denote

F(0,Ut)|C0=F˜(0,z,z¯),

and

F˜(0,z,z¯)=F˜zz′′z22+F˜zz¯′′zz¯+F˜z¯z¯′′z¯22+F˜zzz¯′′z2z¯2+⋯.

For convenience, we rewrite (A.8) as

z˙(t)=iω0z(t)+g(z,z¯),

and denote

g(z,z¯)=g20z22+g11zz¯+g02z¯22+g21z2z¯2+⋯.

From direct calculation, we get

g20=2M¯τ*∫Ωγn03dx(−r−rC1−aC2+aC2e−2iω*τ*C3¯−aC2C4¯),
g11=M¯τ*∫Ωγn03dx[−2r−r(C1+C1¯)−a(C2+C2¯)+a(C2+C2¯)C3¯−a(C2+C2¯)C4¯],
g02=2M¯τ*∫Ωγn03dx(−r−rC¯1−aC¯2+aC¯2e2iω*τ*C3¯−aC¯2C4¯)

and

g21=M¯τ*∫Ω{[−r(2w20(1)(0)+4w11(1)(0))−r(w20(2)(0)+2w11(2)(0)+C¯1w20(1)(0)+2C1w11(1)(0))−a(w20(3)(0)+2w11(3)(0)+C¯2w20(1)(0)+2C2w11(1)(0))]γn02+a(w20(3)(−1)eiω*τ*+2w11(3)(−1)e−iω*τ*+C¯2w20(1)(−1)eiω*τ*+2C2w11(1)(−1)e−iω*τ*)γn02C3¯−a(w20(3)(0)+2w11(3)(0)+C¯2w20(1)(0)+2C2w11(1)(0))γn02C4¯}dx.

Here w11 and w20 are need to be computed. From (A.7), we have

W˙=U˙t−z˙qγn0−z¯˙q¯γn0={AW−2Re{g(z,z¯)q(θ)}γn0,θ∈[−r,0),AW−2Re{g(z,z¯)q(θ)}γn0+F˜,θ=0,≐AW+H(z,z¯,θ), (A.10)

where

H(z,z¯,θ)=H20(θ)z22+H11(θ)zz¯+H02(θ)z¯22+⋯.

Obviously,

H20(θ)={−g20q(θ)γn0−g¯02q¯(θ)γn0,θ∈[−r,0),−g20q(0)γn0−g¯02q¯(0)γn0+F˜zz′′,θ=0,H11(θ)={−g11q(θ)γn0−g¯11q¯(θ)γn0,θ∈[−r,0),−g11q(0)γn0−g¯11q¯(0)γn0+F˜zz¯′′,θ=0,···.

Comparing the coefficients of (A.10) with the derived function of (A.9), we obtain

(A0−2iω0I)W20(θ)=−H20(θ),A0W11(θ)=−H11(θ),⋯. (A.11)

From (A.4) and (A.11), for θ ∈ [−1, 0), we have

W20(θ)=−g20iω*τ*q(θ)γn0−g¯023iω*τ*q¯(θ)γn0+E1e2iω*τ*θ,W11(θ)=g11iω*τ*q(0)eiω*τ*θγn0−g¯11iω*τ*q¯(0)e−iω*τ*θγn0+E2, (A.12)

where E1 and E2 are both 3-dimensional vectors in X, and can be determined by setting θ = 0 in H. In fact, set θ = 0 and by (A.11) and (A.12), we obtain

(A0−2iω*τ*I)E1e2iω*τ*θ|θ=0=−F˜zz′′,A0E2|θ=0=−F˜zz¯′′. (A.13)

The terms F˜zz′′ and F˜zz¯′′ are elements in the space C, and

F˜zz′′=∑n=1∞〈F˜zz′′,βn〉γn,F˜zz¯′′=∑n=1∞〈F˜zz¯′′,βn〉γn.

Denote

E1=∑n=0∞E1nγn,E2=∑n=0∞E2nγn,

then from (A.13) we have

(A0−2iω*τ*I)E1nγne2iω*τ*θ|θ=0=−〈F˜zz′′,βn〉γn,A0E2nγn|θ=0=−〈F˜zz¯′′,βn〉γn,n=0,1,⋯.

Thus, E1n and E2n could be calculated by

E1n=(2iω*τ*I−∫−10e2iω*τ*θdηn(0,θ))−1〈F˜zz′′,βn〉,E2n=−(∫−10dηn(0,θ))−1〈F˜zz¯′′,βn〉,n=0,1,⋯,

where

F˜20=2τ*(−r−rC1−aC2aC2e−2iω*τ*−aC2),
F˜11=τ*(−2r−r(C1+C¯1)−a(C2+C¯2)a(C2+C¯2)−a(C2+C¯2)).

Hence, g21 could be represented explicitly.

Denote

c1(0)=i2ω*τ*(g20g11−2|g11|2−13|g02|2)+12g21,μ=−Re(c1(0))τ*Re(λ′(τ*)),β2=2Re(c1(0)),T2=−1ω*τ*(Im(c1(0))+μ2(ω*+τ*Im(λ′(τ*))). (A.14)

Then by the general Hopf bifurcation theory (see [35]), we know that μ determines the directions of the Hopf bifurcation: if μ > 0(< 0), then the direction of the Hopf bifurcation is forward (backward), that is the bifurcating periodic solutions exist when a > 0(< 0); β2 determines the stability of the bifurcating periodic solutions: the bifurcating periodic solutions are orbitally stable(unstable) if β2 < 0(> 0); and T2 determines the period of the bifurcation periodic solutions: the period increases(decreases) if T2 > 0(< 0).

We now describe briefly the numerical method we use to solve the system (2.5) as follows. For Ω = (0, pπ) × (0, qπ), let xi = ihx, i = 1, 2, ···, l, hx=pπl, yj = jhy, j = 1, 2, ···, m, hy=qπm, tk = kht, ht=τN(N is a positive integer), and u(i, j, k) = u(xi, yj, tk), v(i, j, k) = v(xi, yj, tk), w(i, j, k) = w(xi, yj, tk). We replace ∂u(xi,yj,tk)∂t with a first-order difference u(i,j,k+1)−u(i,j,k)ht, and replace ∂2u(xi,yj,tk)∂x2+∂2u(xi,yj,tk)∂y2 with a second-order difference u(i+1,j,k)−2u(i,j,k)+u(i−1,j,k)hx+u(i,j+1,k)−2u(i,j,k)+u(i,j−1,k)hy. Similarly, we take differences of the partial derivative of v and w. Then, we get a system of difference equations:

{lu(i,j,k+1)=u(i,j,k)+htd1(u(i+1,j,k)−2u(i,j,k)+u(i−1,j,k)hx+u(i,j+1,k)−2u(i,j,k)+u(i,j−1,k)hy)+ht(ru(i,j,k)(1−u(i,j,k)−w(i,j,k)−au(i,j,k)v(i,j,k),w(i,j,k+1)=w(i,j,k)+htd1(w(i+1,j,k)−2w(i,j,k)+w(i−1,j,k)hx+w(i,j+1,k)−2w(i,j,k)+w(i,j−1,k)hy)+ht(au(i,j,k−N)v(i,j,k−N)−w(i,j,k),v(i,j,k+1)=v(i,j,k)+htd2(v(i+1,j,k)−2v(i,j,k)+v(i−1,j,k)hx+v(i,j+1,k)−2v(i,j,k)+v(i,j−1,k)hy)+ht(bw(i,j,k)−au(i,j,k)v(i,j,k−cv(i,j,k).

We implement this method in Matlab, and obtain numerical solutions of the system (2.5).

References

  • [1].Kirn DH, McCormick F Replicating viruses as selective cancer therapeutics. Molecular Medicine Today, 1996, 2(12): 519–527. [DOI] [PubMed] [Google Scholar]
  • [2].Kaplan JM Adenovirus-based cancer gene therapy. Current gene therapy, 2005, 5(6): 595–605. [DOI] [PubMed] [Google Scholar]
  • [3].Roberts MS, Lorence RM, Groene WS, et al. Naturally oncolytic viruses. Current opinion in molecular therapeutics, 2006, 8(4): 314–321. [PubMed] [Google Scholar]
  • [4].Chiocca EA Oncolytic viruses. Nature Reviews Cancer, 2002, 2(12): 938. [DOI] [PubMed] [Google Scholar]
  • [5].Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 1991, 252(5007): 854–856. [DOI] [PubMed] [Google Scholar]
  • [6].Lawler SE, Speranza MC, Cho CF, et al. Oncolytic viruses in cancer treatment: a review. JAMA oncology, 2017, 3(6): 841–849. [DOI] [PubMed] [Google Scholar]
  • [7].Maroun J, Muoz-Ala M, Ammayappan A, Schulze A, Peng KW and Russell S, Designing and building oncolytic viruses, Future Virol. 2017, 12(4), 193–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Chiocca EA and Rabkin SD, Oncolytic viruses and their application to cancer immunotherapy, Cancer Immunol Res. 2014, 2(4): 295–00. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Mok W, Stylianopoulos1 T, Boucher Y, and Jain RK. Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy, Clin Cancer Res. 2009, 15(7): 2352–360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Bajzer Ž, Carr T, Josić K, et al. Modeling of cancer virotherapy with recombinant measles viruses. Journal of theoretical Biology, 2008, 252(1): 109–122. [DOI] [PubMed] [Google Scholar]
  • [11].Friedman A, Tian JP, Fulci G, et al. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer research, 2006, 66(4): 2314–2319. [DOI] [PubMed] [Google Scholar]
  • [12].Novozhilov AS, Berezovskaya FS, Koonin EV, et al. Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models. Biology direct, 2006, 1(1): 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Karev GP, Novozhilov AS, Koonin EV Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics. Biology direct, 2006, 1(1): 30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Wein LM, Wu JT, Kirn D H Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer research, 2003, 63(6): 1317–1324. [PubMed] [Google Scholar]
  • [15].Wodarz D Viruses as antitumor weapons: defining conditions for tumor remission. Cancer research, 2001, 61(8): 3501–3507. [PubMed] [Google Scholar]
  • [16].Wodarz D, Komarova N. Towards predictive computational models of oncolytic virus therapy: basis for experimental validation and model selection. PloS one, 2009, 4(1): e4271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Wu JT, Byrne HM, Kirn DH, et al. Modeling and analysis of a virus that replicates selectively in tumor cells. Bulletin of mathematical biology, 2001, 63(4): 731. [DOI] [PubMed] [Google Scholar]
  • [18].Tian JP The replicability of oncolytic virus: defining conditions in tumor virotherapy. Math. Biosci. Eng, 2011, 8(3): 841–860. [DOI] [PubMed] [Google Scholar]
  • [19].Wang Y, Tian JP, Wei J. Lytic cycle: a defining process in oncolytic virotherapy. Applied Mathematical Modelling, 2013, 37(8): 5962–5978. [Google Scholar]
  • [20].Phan TA, Tian JP The Role of the Innate Immune System in Oncolytic Virotherapy. Computational and Mathematical Methods in Medicine, 2017: 6587258. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Vasiliu D, Tian JP. Periodic solutions of a model for tumor virotherapy. Discrete and Continuous Dynamical Systems S. 2011, 4(6), 1587–1597. [Google Scholar]
  • [22].Boeuf FL, Batenchuk C, Koskela MV, Breton S, Roy D, Lemay C, et al. Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications, 2013, 4:1974. [DOI] [PubMed] [Google Scholar]
  • [23].Choudhury B, Nasipuri B. Efficient virotherapy of cancer in the presence of immune response. Int. J. Dynam. Control, 2014, 2: 314–325. [Google Scholar]
  • [24].Wares J, Crivelli J, Yun CO, Choi IK, Gevertz J, and Kim P. Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. Mathematical Biosciences and Engineering, 2015, 2(6): 1237–1256. [DOI] [PubMed] [Google Scholar]
  • [25].Barish S, Ochs MF, Sontag EO, and Gevertz J. Evaluation optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. PNAS, 2017, E6277–E6286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Mahasa KJ, Eladdadi A, Pillis L d, Ouifki R. Oncolytic potency and reduced vuris tumor-specificity in oncolytic virotherapy, a mathematical modeling approach. PloS ONE, 2017, 12(9): e0184347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Jenner A L, Coster A C F, Kim P S, and Frascoli F Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy. Letters in Biomathematics, 2018, DOI: 10.1080/23737867.2018.1440977 [DOI] [Google Scholar]
  • [28].Ratajczyk E, Ledzewicz U, Leszczynski M, Schattler H. Treatment of glioma with virotherapy and TNF-a inhibitors: analysis as a dynamical system. Discrete and Continuous Dynamical Systems B. 2018, 23(1): 425–441. [Google Scholar]
  • [29].Wodarz D, Hofacre A, Lau JW, Sun Z, Fan H, and Komarova N. Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PloS Computational Biology, 2012, 8(6): e1002547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Wang Z, Guo Z and Peng H. Dynamical behavior of a new oncolytic virotherapy model based on gene variation, Discrete and Continuous Dynamicsal Systems S, 2017, 10(5): 1079–1093. [Google Scholar]
  • [31].Friedman A and Lai X. Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: a mathematical model. PloS ONE, 2018, 13(2): e0192449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Timalsina A, Tian JP, and Wang J. Mathematical and computational modeling for tumor virotherapy with mediated immunity, Bull Math Biol. 2017,79(8): 1736–1758. [DOI] [PubMed] [Google Scholar]
  • [33].Harpold HL, Alvord EC Jr, Swanson KR. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol. 2007, 66(1): 1–9. [DOI] [PubMed] [Google Scholar]
  • [34].Faria T Normal forms and Hopf bifurcation for partial differential equations with delays. Transactions of the American Mathematical Society, 2000, 352(5): 2217–2238. [Google Scholar]
  • [35].Hassard BD, Kazarinoff ND, Wan YH Theory and applications of Hopf bifurcation. Cambridge University Press, 1981. [Google Scholar]
  • [36].Lin X, So JWH, Wu J. Centre manifolds for partial differential equations with delays. Proceedings of the Royal Society of Edinburgh Section A: Mathematics, 1992, 122(3–4): 237–254. [Google Scholar]
  • [37].Wu J. Theory and applications of partial functional differential equations. Springer Science & Business Media, 2012. [Google Scholar]
  • [38].Swanson KR, Alvord EC, and Murray JD, Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy, British Journal of Cancer, 2002, (86): 14–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Massey SC, Rockne RC, Hawkins-Daarud A, Gallaher J, Anderson ARA, Canoll P, and Swanson KR, Simulating PDGF-Driven Glioma Growth and Invasion in an Anatomically Accurate Brain Domain, Bull Math Biol. 2018, (80):1292–309. [DOI] [PubMed] [Google Scholar]

RESOURCES